HUP0104029A2 - A 3-(2,4-diklór-benzil)-2-metil-N-(pentil-szulfonil)-3H-benzimidazol-5-karboxamid új kristályformái és azokat hatóanyagként tartalmazó gyógyszerkészítmények - Google Patents
A 3-(2,4-diklór-benzil)-2-metil-N-(pentil-szulfonil)-3H-benzimidazol-5-karboxamid új kristályformái és azokat hatóanyagként tartalmazó gyógyszerkészítményekInfo
- Publication number
- HUP0104029A2 HUP0104029A2 HU0104029A HUP0104029A HUP0104029A2 HU P0104029 A2 HUP0104029 A2 HU P0104029A2 HU 0104029 A HU0104029 A HU 0104029A HU P0104029 A HUP0104029 A HU P0104029A HU P0104029 A2 HUP0104029 A2 HU P0104029A2
- Authority
- HU
- Hungary
- Prior art keywords
- approximately
- pentylsulfonyl
- dichlorobenzyl
- benzimidazole
- methyl
- Prior art date
Links
- UYGZODVVDUIDDQ-UHFFFAOYSA-N 3-[(2,4-dichlorophenyl)methyl]-2-methyl-n-pentylsulfonylbenzimidazole-5-carboxamide Chemical compound C12=CC(C(=O)NS(=O)(=O)CCCCC)=CC=C2N=C(C)N1CC1=CC=C(Cl)C=C1Cl UYGZODVVDUIDDQ-UHFFFAOYSA-N 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title 1
- 238000002441 X-ray diffraction Methods 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 239000013078 crystal Substances 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- 101100189582 Dictyostelium discoideum pdeD gene Proteins 0.000 abstract 1
- 101150098694 PDE5A gene Proteins 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/10—Radicals substituted by halogen atoms or nitro radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
A találmány vércukorszint-csökkentő vagy PDE5-gátló hatássalrendelkező 3-(2,4-diklór-benzil)-2-metil-N-(pentil-szulfonil)-3H-benzimidazol-5-karboxamid kristályformáira és az ezeket a formákathatóanyagként tartalmazó gyógyszerkészítményekre vonatkozik. A 3-(2,4-diklór-benzil)-2-metil-N-(pentil-szulfonil)-3H-benzimidazol-5-karboxamidnak a találmány szerinti két, lényegileg és kristálytaniszempontból tiszta kristályformájának pormintái a CuK ALFA-sugaraknakmint karakterisztikus röntgensugaraknak az alkalmazásával elvégzettröntgendiffrakciós vizsgálat szerint a következő, <0,2°hibatartománnyal megadott 28 röntgendiffrakciós értékeket mutatják:körülbelül 4,7°, körülbelül 9,5°, körülbelül 10,5°, körülbelül 15,6°és körülbelül 18,4°, illetve körülbelül 4,4°, körülbelül 8,9° éskörülbelül 13,4°. A találmány szerinti gyógyszerkészítményekhatóanyagként az említett két kristályforma egyikét tartalmazzák. Ó
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP32402698 | 1998-11-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0104029A2 true HUP0104029A2 (hu) | 2002-05-29 |
HUP0104029A3 HUP0104029A3 (en) | 2002-07-29 |
Family
ID=18161331
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0104029A HUP0104029A3 (en) | 1998-11-13 | 1999-11-11 | New crystalline forms of 3-(2,4-dichlorobenzyl)-2-methyl-n-(pentylsulfonyl)-3h-benzimidazole-5-carboxamide and medicaments containing them |
Country Status (11)
Country | Link |
---|---|
US (1) | US6703410B1 (hu) |
EP (2) | EP1132087A4 (hu) |
KR (1) | KR20010080444A (hu) |
CN (1) | CN1136196C (hu) |
AU (1) | AU764594B2 (hu) |
BR (1) | BR9915315A (hu) |
CA (1) | CA2350520A1 (hu) |
HK (1) | HK1040078B (hu) |
HU (1) | HUP0104029A3 (hu) |
RU (1) | RU2228931C2 (hu) |
WO (2) | WO2000028991A1 (hu) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000028991A1 (fr) | 1998-11-13 | 2000-05-25 | Fujisawa Pharmaceutical Co., Ltd. | Remedes contre le syndrome des ovaires polykystiques |
WO2000039099A1 (fr) * | 1998-12-24 | 2000-07-06 | Fujisawa Pharmaceutical Co., Ltd. | Derives de benzimidazole |
ATE374028T1 (de) * | 2001-03-27 | 2007-10-15 | Dainippon Sumitomo Pharma Co | Kristallines isoxazol-derivat und medizinisches präparat daraus |
CA2475377A1 (en) * | 2002-02-07 | 2003-08-14 | Pfizer Inc. | Use of pde5 inhibitors such as sildenafil in the treatment of polycystic ovary syndrome |
EP1581247A4 (en) * | 2002-12-11 | 2007-09-12 | Amylin Pharmaceuticals Inc | METHODS AND COMPOSITIONS FOR TREATING STEIN-LEVENTHAL SYNDROME |
US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
US20080194860A1 (en) * | 2006-10-10 | 2008-08-14 | Transform Pharmaceuticals, Inc. | Novel crystal of (s)-(+)-2-(2-chlorophenyl)-2-hydroxy-ethyl carbamate |
CA2769508C (en) | 2009-07-30 | 2020-01-07 | Aestus Therapeutics, Inc. | Methods of treating neuropathic pain with benzimidazole derivative agonists of ppargamma |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3342874B2 (ja) | 1995-04-21 | 2002-11-11 | ニューロサーチ、アクティーゼルスカブ | ベンズイミダゾール化合物、およびgabaaレセプター複合体モジュレーターとしてのその使用 |
CZ293016B6 (cs) * | 1995-06-01 | 2004-01-14 | Sankyo Company Limited | Benzimidazolové deriváty a farmaceutické prostředky s jejich obsahem |
JPH09165371A (ja) * | 1995-10-09 | 1997-06-24 | Sankyo Co Ltd | 複素環化合物を含有する医薬 |
ATE303365T1 (de) | 1995-12-28 | 2005-09-15 | Fujisawa Pharmaceutical Co | Benzimidazolderivate |
AU4400597A (en) * | 1996-10-08 | 1998-05-05 | Fujisawa Pharmaceutical Co., Ltd. | Indole derivatives |
JP3268242B2 (ja) * | 1996-11-14 | 2002-03-25 | 三共株式会社 | 縮合複素環化合物を含有する医薬 |
TW453999B (en) * | 1997-06-27 | 2001-09-11 | Fujisawa Pharmaceutical Co | Benzimidazole derivatives |
CN1150167C (zh) * | 1998-04-06 | 2004-05-19 | 藤泽药品工业株式会社 | 吲哚衍生物 |
WO2000028991A1 (fr) | 1998-11-13 | 2000-05-25 | Fujisawa Pharmaceutical Co., Ltd. | Remedes contre le syndrome des ovaires polykystiques |
-
1999
- 1999-11-10 WO PCT/JP1999/006267 patent/WO2000028991A1/ja not_active Application Discontinuation
- 1999-11-10 EP EP99972100A patent/EP1132087A4/en not_active Withdrawn
- 1999-11-11 CN CNB998143251A patent/CN1136196C/zh not_active Expired - Fee Related
- 1999-11-11 US US09/831,082 patent/US6703410B1/en not_active Expired - Fee Related
- 1999-11-11 AU AU11783/00A patent/AU764594B2/en not_active Ceased
- 1999-11-11 CA CA002350520A patent/CA2350520A1/en not_active Abandoned
- 1999-11-11 BR BR9915315-7A patent/BR9915315A/pt not_active IP Right Cessation
- 1999-11-11 KR KR1020017006041A patent/KR20010080444A/ko not_active Application Discontinuation
- 1999-11-11 HU HU0104029A patent/HUP0104029A3/hu unknown
- 1999-11-11 WO PCT/JP1999/006296 patent/WO2000029383A1/ja not_active Application Discontinuation
- 1999-11-11 EP EP99972205A patent/EP1138674A4/en not_active Withdrawn
- 1999-11-11 RU RU2001116105/04A patent/RU2228931C2/ru not_active IP Right Cessation
-
2002
- 2002-02-26 HK HK02101470.5A patent/HK1040078B/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
RU2228931C2 (ru) | 2004-05-20 |
WO2000028991A1 (fr) | 2000-05-25 |
HUP0104029A3 (en) | 2002-07-29 |
CN1330641A (zh) | 2002-01-09 |
EP1138674A1 (en) | 2001-10-04 |
WO2000029383A1 (fr) | 2000-05-25 |
AU1178300A (en) | 2000-06-05 |
HK1040078A1 (en) | 2002-05-24 |
EP1138674A4 (en) | 2002-08-21 |
CN1136196C (zh) | 2004-01-28 |
US6703410B1 (en) | 2004-03-09 |
HK1040078B (zh) | 2004-07-09 |
CA2350520A1 (en) | 2000-05-25 |
AU764594B2 (en) | 2003-08-21 |
KR20010080444A (ko) | 2001-08-22 |
BR9915315A (pt) | 2001-08-07 |
EP1132087A4 (en) | 2002-06-26 |
EP1132087A1 (en) | 2001-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0102472A2 (hu) | Nitrogén-oxid szintáz inhibitorként alkalmazható amidinoszármazékok, eljárás az előállításukra és a vegyületeket tartalmazó gyógyászati készítmények | |
SG127738A1 (en) | Heterocyclic compounds based on n6-substituted adenine, methods of their preparation, their use for preparation of drugs, pharmaceutical preparations containing these compounds | |
EA200500376A1 (ru) | Триазольные производные в качестве ингибиторов трансформирующего фактора роста (tgf) | |
CA2292984A1 (en) | Ccr5 modulators | |
AU9671798A (en) | Allosteric adenosine receptor modulators | |
NO20061839L (no) | Benzimidazolderivater, sammensetninger inneholdende dem, fremstilling derav, og anvendelse derav | |
IL110494A0 (en) | Perhydroisoindole derivatives, their preparation and pharmaceutical compositions which contain them | |
AU2003294608A1 (en) | Substitution derivatives of n6-benzyladenosine, methods of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds | |
HUP0003757A2 (hu) | Levosimendant tartalmazó orális gyógyászati készítmények | |
NO20030051L (no) | Ny <gamma>-krystallinsk form av perindopril tert- butylaminsalt, fremgangsmåte for dens fremstilling og farmasöytiske sammensetningerinneholdende den | |
NO883229L (no) | Nye benzimidazolderivater, fremgangsmaate for deres fremstilling og farmasoeytisk preparat inneholdende slike derivater. | |
WO2002074056A3 (en) | Allosteric adenosine receptor modulators | |
IT1174474B (it) | Procedimento per la preparazione di formulazione galeniche particolarmente per uso farmaceutico, dietetico, cosmetico e diagnostico | |
HUP0104029A2 (hu) | A 3-(2,4-diklór-benzil)-2-metil-N-(pentil-szulfonil)-3H-benzimidazol-5-karboxamid új kristályformái és azokat hatóanyagként tartalmazó gyógyszerkészítmények | |
NO894616L (no) | Fremgangsmaate for fremstilling av anti-aterosklerotisk aktive diarylforbindelser. | |
RU95111308A (ru) | Производные 2-амино-4-фенил-4-оксомасляной кислоты, способы получения, фармацевтическая композиция | |
WO2002070464A3 (en) | Hydrazones and their therapeutic use | |
HUP0200055A2 (hu) | 16-Hidroxi-ösztratriének és ezeket tartalmazó gyógyszerkészítmények | |
AU580822B2 (en) | New pyrrolobenzimidazoles, processes for the preparation thereof and pharmaceutical compositions containing them | |
DK1124841T3 (da) | Substituerede phenylalkenoylguanidiner, fremgangsmåde til fremstilling deraf, anvendelse deraf som lægemidler eller diagnosemidler og lægemidler, som indeholder dem | |
SE0302572D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
HUP9802897A2 (hu) | Optikailag aktív piridil-4H-1,2,4-oxadiazin-származék, annak alkalmazása vaszkuláris betegségek kezelésére, valamint ilyen származékot hatóanyagként tartalmazó gyógyászati készítmény | |
IT1234218B (it) | Derivati terziobutilati di benzilidene canfora, procedimento per la loro preparazione,loro impiego come agenti anti ossidanti e composizioni cosmetiche e farmaceutiche che li contengono | |
HUP0001738A2 (hu) | Etil-(Z)-2-klór-3-[2-klór-5-(4,5,6,7-tetrahidro-1,3-dioxo-izoindoldion-2-il)-fenil ]-akrilát folyékony formázású készítménye | |
WO2004056832A3 (en) | Epothilone derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB9A | Succession in title |
Owner name: DAICEL CHEMICAL INDUSTRIES, LTD., JP Free format text: FORMER OWNER(S): FUJISAWA PHARMACEUTICAL CO., LTD., JP; DAICEL CHEMICAL INDUSTRIES, LTD., JP; YAMANOUCHI PHARMACEUTICAL CO., LTD., JP Owner name: ASTELLAS PHARMA INC., JP Free format text: FORMER OWNER(S): FUJISAWA PHARMACEUTICAL CO., LTD., JP; DAICEL CHEMICAL INDUSTRIES, LTD., JP; YAMANOUCHI PHARMACEUTICAL CO., LTD., JP |